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Background:  Acute-on-chronic  liver  failure  (ACLF)  is an entity  comprising  an acute  deterioration  of  liver
function  in cirrhotic  patients,  associated  with  organ  failure(s)  and  high  short-term  mortality.  We  aimed
to identify  predictive  factors  for short-term  mortality  in  patients  admitted  with  ACLF that may  benefit
most  from  liver  transplantation.
Methods: Retrospective  analysis  of  patients  admitted  in  ACLF  to a tertiary  intensive  care  unit  between
2013  and  2017  was  performed.  The  EASL-CLIF  acute-on-chronic  liver  failure  in  cirrhosis  (CANONIC)  cri-
teria were  used  to define  ACLF  grade.  Multivariable  analysis  using  28-day  mortality  as an  end-point  was
performed,  including  severity-of-disease  scores  and  clinical  parameters.
Results:  Seventy-seven  patients  were  admitted  in ACLF  over  the  study  period.  The  common-
est aetiology  of liver  disease  was  alcohol  related  52/77(68%)  and  the commonest  precipitant
of ACLF  was variceal  haemorrhage  38/77(49%).  Overall  28-day  mortality  was  42/77(55%)  [ACLF-
(grade)1:3/42(7%);  ACLF-2:10/42(24%);  and,  ACLF-3:29/42(69%);p = 0.002].  On  multivariable  analysis
MELD  ≥ 26  [odds  ratio(OR)  =  11.559;  95%  confidence  interval(CI):2.820–47.382;p  = 0.001],  ACLF-3
(OR  =  3.287;  95%CI:1.047–10.325;p = 0.042)  at admission  and  requirement  for renal  replacement  therapy
(OR  =  5.348;  95%CI:1.385–20.645;p = 0.015)  were  independently  associated  with  28-day  mortality.
Conclusion:  Patients  admitted  with  ACLF  to intensive  care  have  a high  mortality  rate.  Defined  early thresh-
olds  at  admission  can identify  patients  at the highest  risk  that  may  benefit  most  from  liver transplantation.
Crown  Copyright
©  2019  Published  by Elsevier  Ltd on behalf  of  Editrice  Gastroenterologica  Italiana  S.r.l.  All  rights  reserved.. Introduction
Acute-on-chronic liver failure (ACLF) is an entity defined by an
cute deterioration in liver function in a patient with established
hronic liver disease. Generally the condition is precipitated by a
uper-added acute hepatic injury or an extrahepatic factor which
ould be treated, and therefore this is a potentially reversible con-
ition [1,2]. Despite this feature, ACLF has a short-term mortality
s high as 50–90% [1,3]. Identification of the precipitating factor is
∗ Corresponding author at: The Liver Unit, Queen Elizabeth Hospital Birmingham,
irmingham, B15 2TH, United Kingdom.
E-mail address: Thamara.Perera@uhb.nhs.uk (M.T.P.R. Perera).
ttps://doi.org/10.1016/j.dld.2019.04.008
590-8658/Crown Copyright © 2019 Published by Elsevier Ltd on behalf of Editrice Gastrcrucial for early commencement of specific treatments, which may
avoid the development of organ failure(s) and consequent patient
death.
The severity of the ACLF episode can be classified according
to the chronic liver failure consortium (CLIF-C) sequential organ
failure assessment (SOFA) - CLIF-SOFA - score. This classification
originated from the chronic liver failure (CLIF) consortium acute in
chronic (CANONIC) study and places patients at 3 grades of risk
depending on the number of organ failures [1]. Importantly, an
increased number of organ failures correlates with an increased 28-
day mortality rate. Patients with failure in 1 system (ACLF-1) had a
mortality of 23% increasing to around 74% in the case of 3 system
organ failure (ACLF-3) [1]. In a previous cohort study of 388 patients
admitted with ACLF, reported by Gustot et al. 49.2% improved fol-
oenterologica Italiana S.r.l. All rights reserved.
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owing admission whereas 30.4% had a fluctuating disease course
hile a further 20.4% deteriorated in clinical condition [4]. How-
ver, subgroup analysis according to disease severity showed that
hese rates varied; for ACLF-1 patients 54.5% developed resolu-
ion of the episode whereas only 16% of those in the ACLF-3 group
ecovered [4].
Liver transplantation (LT) is a life-saving procedure considered
n some studies mainly for ACLF-3 patients [1,4]. In the CANONIC
tudy patients with more than two organ failures that received
 LT had a mortality rate of 20% in comparison with more than
0% for patients that did not undergo LT [1]. Nevertheless, it is
till not understood when the optimal time for the assessment of
he patients is, what the indication for the procedure should be
nd which patients would benefit most from it. A detailed discus-
ion about unresolved issues regarding LT for ACLF patients can be
ound in a recent review article [5]. The early identification of pre-
ictive factors for an inferior prognosis and a fatal outcome within
n appropriate narrow window of opportunity could potentially
elect patients for LT before irreversible multiple organ failure and
rogression of ACLF grade occurs. Currently in the United King-
om (UK) there is no formal consideration of LT in patients with
CLF, although anecdotally individual centres may  have offered LT
or selected patients with an acute deterioration of liver function.
t is possible that the growing evidence base to support LT in ACLF
etting, in conjunction with careful identification and patient selec-
ion, could provide hope for some patients with ACLF. Therefore, the
im of this study was to identify independent early predictors for
8-day mortality rate in patients admitted with ACLF to the inten-
ive care unit (ICU) and define possible thresholds where LT most
ikely becomes a life-saving treatment option to be considered.
. Patients and methods
.1. Study design
A retrospective analysis of the outcomes of patients with a diag-
osis of ACLF admitted to the Queen Elizabeth Hospital Birmingham
iver intensive care unit between January 2013 and December 2017.
he diagnosis of ACLF was made based on pre-defined criteria [6]
nd its severity graded according to the CLIF-SOFA score [1]. The
8-day mortality rate was analysed for the entire cohort and strat-
fied according to episode severity. Predictive factors using 28-day
ortality as an endpoint were identified and suggested as possible
hresholds for unrecoverable ACLF episodes.
.2. Study population
The records of admission diagnoses to the ICU over the period
f study were screened for the presence of liver diseases. Patients
hat had a liver related cause for admission were collated with the
edical records to ascertain the degree of chronic liver disease and
he presence of diagnostic criteria for ACLF as described below.
.3. Identification of ACLF
The diagnosis of ACLF was based on the European and American
ssociations for the Study of Liver Disease, as an “acute deterio-
ation of pre-existing, chronic liver disease, usually related to a
recipitating event and associated with increased mortality at 3
onths due to multi-system organ failure” [6]. The severity of the
CLF episode was classified according to the CLIF-SOFA score based
n the number of organ failures [1]. The CLIF-SOFA scores 6 com-
onents (liver, kidneys, brain, coagulation, circulation and lungs)
rom 0 to 4, rising accordingly to more severe organ impairment
1]. Parameters to define organ failures and the definition of ACLF
rades are described in the Supplementary Tables S1 and S2, in Liver Disease 51 (2019) 1416–1422 1417
accordance with the CANONIC study. Septic shock was  defined
as the occurrence of acute organ dysfunction secondary to docu-
mented or suspected infection and in the presence of hypotension
not reversed with fluid resuscitation [7].
2.4. Data collection
Demographic data (age, sex, body mass index [BMI], presence of
type 2 diabetes mellitus, sarcopenia and other comorbidities, aeti-
ology of the liver disease) was  retrieved for analysis. Sarcopenia was
assessed by a liver specialist dietician using anthropometry (hand
grip, mid-arm muscle circumference, triceps skin-fold thickness)
and calculated target body weight for height/age. If the patient was
unable to perform a hand grip, a subjective assessment was made
by the bedside by two  clinicians. Laboratory data at ICU admis-
sion and after 48–72 h were recorded to assess the severity of liver
disease: platelet count, C-reactive protein (CRP), white cell count
(WCC), albumin levels, international normalized ratio (INR), crea-
tinine, bilirubin, and serum sodium levels. The length of ICU and
hospital stay, the number and type of organ failures, the primary
reason for admission, 28-day, 90-day, and 1-year mortality rates
were also recorded. Prognostic score indices for the severity of
liver disease (Model for End-Stage Liver Disease [MELD] [8,9] and
United Kingdom Model for End-Stage Liver Disease [UKELD] [10])
and for the severity of the acute deterioration (Acute Physiology
and Chronic Health Evaluation II [APACHE II] [11] were calculated.
2.5. Statistical analysis
Categorical variables were described and analysed using abso-
lute number and frequency (percentage) and compared using
Pearson’s chi-squared test or Fisher’s exact test. Continuous vari-
ables were described using median (interquartile range) or mean
(standard deviation) depending on distribution (assessed by the
Shapiro–Wilk test) and analysed using Student’s t-test for para-
metric and Mann–Whitney U Test for non-parametric variables.
Variables with a p-value less than 0.20 were entered into multivari-
able analysis model to identify independent predictors of 28-day
survival. Multivariable analysis was  conducted using a binary logis-
tical regression model, with stepwise backward elimination of
variables. Survival was estimated using Kaplan–Meier plots with
log–rank tests for differences. Prior to the multivariable analysis,
significant continuous variables were dichotomised to increase the
practical applicability of our data. The Youden’s index was defined
from the receiving operating characteristic (ROC) curve analysis in
an attempt to identify optimal cutoff values for dichotomisation.
However, this did not find any cutoffs that were clearly superior,
hence the median values were used. To prevent a biased regres-
sion coefficient as a result of data-driven cutoffs values based on
information from the entire cohort, each factor was also tested as
a continuous variable, a process which returned similar results, in
the univariable analysis. Collinearity between explanatory survival
variables was  tested using Cramer’s V test and Spearman’s rank cor-
relation coefficients, and highly correlated variables were excluded
from the analysis to prevent issues with multicollinearity. For all
the tests a p < 0.05 was considered as statistically significant. Statis-
tical analysis tests were performed using SPSS version 24 software
(IBM Corp, Armonk, NY).
3. Results
During the period of study 77 patients were admitted to the
ICU fulfilling the criteria of ACLF. Data from more than 95% of
patients was available for each individual variable analysed. For
the entire cohort, 49/77 (64%) were male, the median age was
51 years (Interquartile range: 43–57), CLIF-SOFA score 12 (10–14),
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Table 1
Clinical variables, distribution of cut offs for severity-of-disease scores at admission and organ support requirement for patients admitted to intensive care unit with
acute-on-chronic liver failure. Descriptive analysis for the entire cohort and comparison between 28-day mortality groups.
Variable All patients
(n = 77)
28d survivors
(n = 35)
28d non-survivors
(n = 42)
p value
Age, years 50(±11) 51 (±12) 50 (±9) 0.891
Body  mass index (kg/m2) 30 (25–35) 28 (24–35) 31 (26–34) 0.160
Female sex [%(n)] 36 (28/77) 43 (15/35) 31 (13/42) 0.280
Diabetes [%(n)] 25 (19/77) 34 (12/35) 17 (7/42) 0.074
Sarcopenia [%(n)] 17 (13/77) 14 (5/35) 19 (8/42) 0.579
Aetiology chronic liver disease
0.695
ALD [%(n)] 57 (44/77) 57 (20/35) 57 (24/42)
ALD  + other [%(n)] 10 (8/77) 23 (8/35) 0 (0/42)
NASH [%(n)] 9 (7/77) 6 (2/35) 12 (5/42)
PSC  [%(n)] 8 (6/77) 6 (2/35) 10 (4/42)
PBC  [%(n)] 6 (5/77) 9 (3/35) 5 (2/42)
Others [%(n)] 9 (7/77) 0 (0/35) 17 (7/42)
Primary reason for admission
0.174
Variceal bleeding [%(n)] 49 (38/77) 63 (22/35) 38 (16/42)
Septic  shock [%(n)] 22 (17/77) 11 (4/35) 31 (13/42)
Active alcoholism [%(n)] 4 (3/77) 3 (1/35) 5 (2/42)
Others [%(n)] 25 (19/77) 23 (8/35) 26 (11/42)
Variceal bleeding on admission [%(n)] 49 (38/77) 63 (22/35) 38 (16/42) 0.041
Distribution of cutoffs for severity-of-disease scores at admission
ACLF grade 3 [%(n)] 51 (39/77) 29 (10/35) 69 (29/42) 0.001
CLIF-SOFA > 12 [%(n)] 61 (47/77) 40 (14/35) 79 (33/42) 0.001
UKELD > 61 [%(n)] 49 (38/77) 16 (12/35) 34 (26/42) 0.016
MELD  > 26 [%(n)] 53 (41/77) 29 (10/35) 74 (31/42) 0.001
Length of ICU stay (days) 8 (5–14) 9 (4–17) 7 (5–12) 0.570
Length of hospital stay (days) 17 (11–35) 26 (16–46) 14 (10–25) 0.003
Survival (days) 18 (8–316) 335 (50–1018) 9 (5–15) 0.001
Mechanical ventilation [%(n)] 69 (53/77) 66 (23/35) 71 (30/42) 0.590
Inotropes requirement [%(n)] 58 (45/77) 54 (19/35) 62 (26/42) 0.499
Renal  replacement therapy [%(n)] 60 (46/77) 40 (14/35) 76 (32/42) 0.001
Continuous variables presented as median (IQR) or mean (±SD) based on the normality of the distribution. Bold p-values are significant at p < 0.05. Abbreviations: 28d —
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ELD  — model for end-stage liver disease; ICU — intensive care unit.
ELD 26 (18–32) and UKELD 61 (53–67). Thirty-eight out of 77
atients (49%) had variceal bleeding as the primary reason for the
evelopment of ACLF and 17/77 (22%) an infectious event with sep-
ic shock (Table 1). No significant association was found between
he severity of ACLF and the identifiable precipitating trigger for
ts development (Table S3). Alcoholic liver disease alone was the
ost prevalent cause of the background chronic liver disease (68%)
44/77 alcoholic liver disease alone and 8/77 associated with co-
xisting aetiologies) followed by non-alcoholic steatohepatitis with
/77 (12%). Nineteen patients (25%) consumed alcohol in the three
onths preceding the index admission to ICU.
Twelve patients (38%) were active on the transplant waiting
ist already, from those 4/12 died within 28 days before being
ransplanted, 5/12 within 1 year and 3 patients were transplanted.
ne transplanted patient was admitted in ACLF-1, this was  sta-
le within the initial 48–72 h of hospitalisation and transplantation
as undertaken after 58 days; the other 2 patients were discharged
rom hospital and transplanted later. From the remaining patients
n = 65), 3 patients were transplanted, 2 within the index admis-
ion and 1 later, after discharge. Forty-one out of sixty-five (63%)
atients died within 1 year after the index admission (38 within
8 days and 3 within 1 year). Overall, twelve out of seventy-seven
16%) patients had a clinical deterioration over the initial 48–72 h
f hospitalisation. From those 3/12 (25%) died within 28 days and
/12 (42%) died within 90 days.
.1. Severity of ACLFAt admission over half of patients were classified as ACLF-3
39/77 [51%]), followed by ACLF-2 (29/77 [38%]). ACLF-1 was  the
mallest group [9/77 (12%)]. By day 3 of ITU admission, 45/77 (58%)
atients were ACLF-3, 20/77 (26%) ACLF-2, 7/77(9%) ACLF-1. At theary sclerosing cholangitis; PBC — primary biliary cirrhosis; ACLF — acute-on-chronic
e assessment (SOFA); UKELD — United Kingdom model for end-stage liver disease;
same time point (72 h) one ACLF-3 patient had died and only 4/77
(5%) patients had completely recovered from the ACLF episode (one
ACLF-3 and three ACLF-2 patients — none were transplanted dur-
ing index admission). Six out nine (67%) ACLF-1 patients remained
in the same ACLF grade along the first 48–72 h of admission, this
proportion was  similar for ACLF-2 patients 20/29 (69%) and even
higher 34/39 (87%) for ACLF-3 patients. Table 2 and Fig. 1 depicts the
pattern of evolution of disease parameters along the time course.
3.2. Mortality in ACLF
The overall 28-day mortality rate was 42/77 (55%). Mortality
rate increased with severity of the ACLF episode at admission [33%
for ACLF-1, 35% ACLF-2 and 74% for ACLF-3; p = 0.003] (Fig. 2).
Retrospectively reviewing the trends of mortality, this difference
was still significant at 48–72 h of admission and a higher mortal-
ity could be predicted based on severity alone [14% ACLF-1, 51%
ACLF-2 and 65% ACLF-3; p = 0.039]. Importantly the 28-day mortal-
ity rate was  not dictated by short-term clinical evolution (48–72 h)
as 37/42 (88%) of patients who  died had a stable disease course over
this 48–72 h period. Median survival (days) decreased according to
ACLF severity, being 312 (15–776) days for ACLF-1, 37 (10–540) for
ACLF-2 and 12 (6–41) for ACLF-3 (p = 0.032).
Only two variables were statistically significant on the univari-
able analysis after 48–72 h from admission that were not significant
at admission (platelet and white cell counts). In order to enhance
the practical applicability of our data as a future adjuvant tool to
select patients for LT, we  defined cutoffs for significant continuous
risk factors for 28-day mortality (Tables 1 and 2) at admission. Cut-
offs for CLIF-SOFA score (12 points), MELD (26 points), UKELD (61
points) and ACLF grade (grade 3) were defined based on the median
values, as there were not significant superior values by the Youden’s
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Table  2
Distribution and comparison of laboratory results and severity of disease scores at admission and after 48–72 h, for patients admitted with acute-on-chronic liver failure in
the  intensive care unit.
Variable All patients
(n = 77)
28d Survivor
(n = 35)
28d Non-
survivors
(n = 42)
p value All patients
(n = 77)
28d Survivors
(n = 35)
28d Non-
survivors
(n = 42)
p value
At  admission Data after 48–72 h after admission
ACLF grade*
No ACLF n/a 5 (4/77) 11 (4/35) n/a n/a
Grade  1 [%(n)] 12 (9/77) 17 (6/35) 7 (3/42)
<0.001
9 (7/77) 17 (6/35) 2 (1/42)
0.011Grade 2 [%(n)] 38 (29/77) 54 (19/35) 24 (10/42) 26 (20/77) 26 (9/35) 26 (11/42)
Grade 3 [%(n)] 51 (39/77) 29 (10/35) 69 (29/42) 58 (45/77) 46 (16/35) 69 (29/42)
Deceased n/a 1 (1/77) n/a 1 (1/42) n/a
CLIF-SOFA score 12 (10–14) 10 (10–12) 13(12–14) <0.001 13 (11–15) 11 (10–13) 14 (12–16) <0.001
Platelet (x109/L) 70 (51–98) 71 (51–111) 66 (48–90) 0.416 61 (±34) 69 (±37) 55 (±31) 0.019
CRP  (mg/L) 37 (17–69) 24 (16–59) 48 (21–86) 0.057 48 (29–69) 46 (27–65) 53 (32–76) 0.370
White  blood cells (x109/L) 10.5 (6.0–14.8) 9.1 (5.6–13.1) 11.8 (7.3–15.6) 0.067 10.7 (±5.8) 8.3 (±4.0) 12.8 (±6.3) 0.001
Albumin (g/L) 30(±8) 30 (±8) 31 (±7) 0.863 30 (26–35) 30 (26–34) 31 (27–35) 0.650
INR  1.8 (1.6–2.4) 1.6 (1.4–2) 2.2 (1.7–2.7) 0.001 2.1 (±0.6) 1.8 (±0.5) 2.3 (±0.7) <0.001
Creatinine (mmol/L) 112 (80–194) 100 (62–135) 140 (94–216) 0.025 99 (72–148) 76 (57–119) 121 (85–176) 0.001
Bilirubin (mg/dL) 123 (52–373) 69 (29–272) 177 (82–406) 0.003 216 (±177) 177 (±176) 254 (±170) 0.010
Sodium (mEq/L) 136 (129–142) 137 (126–142) 135 (129–142) 0.619 139 (136–145) 142 (137–145) 135 (139–143) 0.206
UKELD 61 (53–67) 55 (52–65) 63 (57–68) 0.047 58 (±7) 53 (51–58) 61 (57–63) 0.001
MELD  26 (17–32) 18 (15–29) 28 (23–34) <0.001 19 (16–25) 19 (16–25) 28 (23–33) <0.001
APACHE II 20 (16–26) 18 (15–24) 21 (17–27) 0.162
Encephalopathy** [%(n)] 21 (16/77) 23 (8/35) 19 (8/42) 0.143 64 (49/77) 54 (19/35) 71 (30/42) 0.074
Continuous variables presented as median (IQR) or mean (±SD) based on the normality of the distribution. Bold p-values are significant at p < 0.05. *According to the CLIF-SOFA
score.  **According to the West Haven Classification. Abbreviations: n/a — not applicable; ACLF — acute-on-chronic liver failure; CLIF-SOFA — chronic liver failure consortium
(CLIF-C) sequential organ failure assessment (SOFA); CRP — C-reactive protein; INR — International normalized ratio; UKELD — United Kingdom model for end-stage liver
disease;  MELD — model for end-stage liver disease.
Fig. 1. Flow diagram of progression of grades of acute-on-chronic liver failure (ACLF) pati
mortality endpoint.
Fig. 2. Short-term and mid-term mortality rates for patients with acute-on-chronic
liver failure admitted to the intensive care unit, Queen Elizabeth Hospital, Birming-
ham, United Kingdom, 2013–2017.
The short-term (28-day) and mid-term (90-day) mortality rates for patients admit-
ted with acute-on-chronic liver failure (ACLF) increased following an increase in the
severity of disease as assessed by the ACLF grade score based on the number of organ
failure(s). In all panels the bar represents the mortality rate at the time points for
each group. Comparison between groups used Pearson’s chi-squared test. Statistical
significance at *p < 0.05.ents admitted to the intensive care unit and their outcomes considering the 28-day
index analysis from the ROC curve (data not shown). Requirement
for mechanical ventilation and inotropic support were not pre-
dictive factors for 28-day mortality on the univariable analysis.
However, the need for renal replacement therapy was  associated
with an increased risk of mortality (p = 0.001). Tables 1 and 2 show
the differences between 28-day survivors vs. non-survivors follow-
ing the index admission (univariable analysis).
3.3. Predictors of mortality
A multivariable logistical regression analysis was performed
to identify independent predictors of 28-day mortality follow-
ing admission on ICU due to ACLF. MELD score and ACLF grade
had the defined cutoffs included in the analysis. Due to a highly
significant correlation between: (1) CLIF-SOFA and ACLF grade
(Spearman’s correlation = 0.855); and, (2) UKELD and MELD scores
(Spearman’s correlation = 0.802); the CLIF-SOFA and UKELD scores
were excluded from the multivariable analysis to prevent issues
with multicollinearity. Three independent risk factors for 28-day
mortality were identified; results are presented in Table 3.
Patients with a MELD score greater than 26 points at admission
had a higher short-term mortality rate as represented by the 1-year
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Table 3
Multivariable analysis of predictive factors associated with 28-day mortality in
patients with acute-on-chronic liver failure.
Variable Odds ratio
(OR)
95% Confidence
Interval
p value
MELD ≥ 26 11.559 2.82–47.382 0.001
ACLF grade 3 3.287 1.047–10.325 0.042
Renal replacement therapy 5.348 1.385–20.645 0.015
All factors from Tables 1–3 with p < 0.2 were considered for inclusion in a backward
stepwise multivariable model. For severity-of-disease score (MELD, and ACLF grade)
cut off values defined by median were used instead of the continuous variables. Body
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Fig. 3. Kaplan–Meier survival curves for patients with acute-on-chronic liver failure
admitted to the intensive care unit, Queen Elizabeth Hospital, Birmingham, United
Kingdom, 2013–2017.
The Kaplan–Meier survival curves show the 1-year mortality rate for entire cohort ofass index (kg/m2), diabetes mellitus, C-reactive protein (CRP), white blood cells,
nternational normalized ratio (INR), creatinine, bilirubin, APACHE II score were
xcluded by the stepwise procedure. Bold values are significant at p < 0.05.
aplan–Meier survival curve (Log–Rank test p < 0.001). A simi-
ar figure was seen for ACLF-3 patients (Log–Rank test p = 0.005)
nd the requirement for renal replacement therapy (Log–Rank test
 = 0.022) (Fig. 3).
. Discussion
Over the past decade ACLF has gained growing attention from
rofessionals involved in the field of LT. Despite a potential treat-
ble condition, it carries alarmingly high short-term mortality rates
1–3]. LT was shown previously as a potentially successful approach
o increase survival rates for a highly selected group of patients
1]. Nevertheless, the correct timing and criteria for LT in this set-
ing is still not defined [5]. This study showed that MELD score
reater than 26, ACLF-3 at admission and the requirement for renal
eplacement therapy were independent predictive factors for 28-
ay mortality in ACLF patients admitted on ICU. More importantly,
hose factors were already found to be significant at admission to
he ICU and the clinical evolution within the ensuing 48–72 h did
ot differentiate patients with an inferior outcome once stabilised
ith established organ support on ICU. This finding is relevant
ecause it shows that these early admission predictive factors could
dentify patients at the highest risk of death, thereby, offering a
mall window of time when a select group of patients could be
ssessed for suitability for LT.
The majority of patients admitted in ACLF to ICU had a severe
orm of disease requiring multiple organ support. Failure of three
r more organs systems was the most prevalent scenario in our
ohort and this is likely to be related to the inclusion of patients
dmitted exclusively to ICU. Short-term mortality rate (28-day) was
round 55% and it increased significantly following an increase in
he severity of disease at admission. Dynamic changes in the clin-
cal evolution of patients in the first 72 h from admission did not
redict overall outcome. Whilst clinical deterioration is still asso-
iated with high mortality rates, most patients had a stable course
f disease along this period. Conversely, Gustot et al. reported that
9.2% of patients admitted in ACLF improved and that the ACLF
rade assessed between days 3–7 was a better predictor of 28-
ay mortality than at admission [4]. We  attribute this difference
argely due to variations in cohort composition and the inclusion
f patients admitted to ICU only; 51% of our patients (n = 39) had
CLF-3 at admission versus 13% at the former study (n = 50). In fact,
onsidering only the cohort of ACLF-3 patients in that study, 68% of
atients had a stable course of disease [4]. The higher prevalence
f most severe forms of disease in our cohort is attributed to the
act that those patients have not been clinically stabilised previ-
usly. For these sickest patients, sudden clinical improvements are
are and timely interventions may  avoid deterioration and patient
eath, whereas few patients have (5/77 [6%]) completely recovered
r died over these initial 72 h.
patients according with the occurrence at admission of a Model for End Stage Liver
Disease (MELD) greater than 26 (Graph A), acute-on-chronic liver failure (ACLF)
with presence of 3 or more organ failures (ACLF-3) (Graph B) and the requirement
for  renal replacement therapy (Graph C). The log–rank test was used to compare the
differences in survival. A p < 0.05 was considered as statistically significant.
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Currently in the United Kingdom there is no clinical guideline
efining timings and criteria for listing patients in ACLF for LT.
atient assessment, indication of the procedure and definition of
utility is entirely based on the experience of the team. The vast
ajority of patients in our cohort had not been previously assessed
or LT prior to ICU admission and 38/65 (58%) died within 28 days.
his raises a need of developing a protocol for the early identifica-
ion of potential candidates for LT and offering this option whilst
hey are in the ICU. Our proposal is supported by the CANONIC study
4] where a 1-year survival of 75% was reported in the group that
nderwent LT in ACLF, including those with ACLF-3 within the first
8-days from the diagnosis. The median time for transplantation
as 11 days.
Before the CANONIC study in 2013 there was no consensus for
CLF definition, making comparison with more recent studies diffi-
ult. However, in a study involving 175 patients with ACLF (defined
s a sudden increase in the MELD score of more than 5 within
 weeks before transplantation) there were no differences in 3-
ear survival between ACLF patients and non-ACLF patients that
ad liver only transplantation [12]. Furthermore living donor liver
ransplantation using right lobe grafts was reported in a case-series
f 32 ACLF patients [13]. Within a follow-up period of 23 months,
raft survival was 82% and patient survival 84%, both comparable to
ates of non-ACLF patients [13]. Other studies have also successfully
sed living donor liver transplantation in this context reporting
imilar survival rates [14,15].
In accordance with our findings, renal dysfunction has been
ssociated with an inferior prognosis for patients with chronic liver
isease during an episode of acute deterioration [12,16]. In an anal-
sis of 64 patients admitted to ICU in ACLF, the incidence of renal
ysfunction was 58% and was associated with a 28-day mortal-
ty rate of 100% [17]. This mortality rate could not be improved
ith the use of continuous renal replacement therapy [17]. Stud-
es reporting the use of renal replacement therapy in patients with
ecompensated liver cirrhosis showed that challenges start at the
election of the modality to use (intermittent haemodialysis or con-
inuous renal replacement therapy) [18]. Regarding aetiology, it is
peculated that the causes for renal dysfunction in patients in ACLF
iffer from those in acute decompensations of chronic liver disease
nd hepatorenal syndrome [3]. It is hypothesised that as inflam-
ation is a fundamental part of ACLF pathogenesis [19] it may  play
 significant role in renal injury as well as circulatory dysfunction.
owever, a precise understanding of the importance of different
ndividual components of renal dysfunction in ACLF is still lack-
ng [3]. Despite this, some previous studies exploring the use of
nti-inflammatory agents such as N-acetylcysteine [20] and pen-
oxifylline [21] in patients with hepatorenal syndrome showed a
ositive impact on renal function. Whether these therapies hold
linical benefit for the renal dysfunction of ACLF remains unclear.
Recently the United Kingdom has adopted a national alloca-
ion system that utilises a patient benefit score. This score takes
nto account both recipient and donor parameters. A hypotheti-
al scenario where an ACLF patient is admitted to ICU with high
rgan support requirements may  yield high patient benefit scores,
hereby, increasing the chances of organ allocation to such patients
f listed. The identification of patients that are at a high risk of
eath is fundamental for an early discussion in order to list such
atients. UKELD score was a significant predictor of 28-day mortal-
ty in our univariable analysis, however it was excluded from the
ultivariable analysis due to issues with multicollinearity. MELD
core and the ACLF grade were both independent predictors of 28-
ay mortality for patients admitted in ACLF to ICU, those factors
aving been associated in other studies with a poor prognosis too
1,3,4,22]. On the contrary, patients with an active alcohol history
t the time of an acute deterioration or decompensation poten-
ially causes concerns about this patient group when considering Liver Disease 51 (2019) 1416–1422 1421
LT, whereas other benign and non-self-inflicted aetiologies should
perhaps be considered favourably.
Limitations of this study include its retrospective nature and the
relatively small number of patients. Despite using a broad screen-
ing methodology, we  may  have lost some cases along the period of
study. Moreover, to date, no patient identified at high-risk of 28-day
mortality according to our criteria was transplanted. Apart from the
identification of the highest-risk patients, other variables are still
needing definition for their management, such as the development
of a priority system, definition of the best organ supports avail-
able and clinical management until transplantation. However, this
study provides an initial orientation towards an improvement in
the assistance for severely ill patients in ACLF, not only to our ser-
vice but highlights important points for an area in development.
Whilst we  have highlighted the importance of early identification
of subjects at high risk of short-term mortality, we acknowledge
that their individual clinical evolution needs to be taken into con-
sideration during assessment for transplantation.
5. Conclusion
In conclusion, patients admitted in ACLF to ICU showed
extremely high mortality rates that increased following a worsen-
ing of their clinical condition and liver function. MELD score greater
than 26, ACLF grade 3 and requirement of renal replacement ther-
apy were identified as predictive factors for 28-day mortality, and
cutoffs were defined for easier clinical identification of patients at
high risk of death. Importantly, these factors were as relevant at
admission as after short-term clinical follow-up. This finding is cru-
cial in ACLF patients for whom it is likely that a very narrow window
of opportunity is available before significant clinical deterioration
occurs and futility is considered by treating clinicians. Early iden-
tification of patients at the highest risk of such deterioration and
where LT is potentially the only life-saving approach is the first step
towards an improvement in the management of severely ill ACLF
patients.
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